← Back to Clinical Trials
Recruiting NCT06524843
Fracture Risk Evaluation of Bone Metastases Derived From Carcinoma
Trial Parameters
Condition Bone Metastases
Sponsor Costantino Errani
Study Type OBSERVATIONAL
Phase N/A
Enrollment 250
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-09-23
Completion 2026-12
Interventions
Analysis
Brief Summary
From the archives of the Rizzoli institute all patients (approximately 750) treated for bone metastases from 01/01/2010 to 31/12/2022. A review will be made from the medical records, radiological imaging, and histological data of these patients
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Diagnosis of bone metastasis from carcinoma, regardless of the type of carcinoma, and of the number and location of the metastases * Availability of imaging and clinical data * Availability of at least one follow-up during the last 12 months form diagnosis Exclusion Criteria: * At least one inclusion creteria not met
Related Trials
NCT05825456
Metastatic Pathologic Fractures, Short Term Results
View Trial →
NCT06918860
Analysis of Intramedullary Nail and Prosthetic Reconstruction After Surgical Treatment of Bone Metas
View Trial →
NCT06538896
Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breas
View Trial →